Your browser is no longer supported. Please, upgrade your browser.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite Help
publish chart | save to portfolio | create alert Type: candle | line | advanced | interactive | perf    Timeframe: intraday | daily | weekly | monthly  Settings
INCY Incyte Corporation daily Stock Chart
INCY [NASD]
Incyte Corporation
Healthcare | Biotechnology | USA
statements
IndexS&P 500 P/E- EPS (ttm)-1.74 Insider Own0.80% Shs Outstand216.72M Perf Week6.27%
Market Cap22.59B Forward P/E27.62 EPS next Y3.90 Insider Trans-12.46% Shs Float214.49M Perf Month14.91%
Income-376.00M PEG- EPS next Q0.87 Inst Own94.20% Short Float3.63% Perf Quarter37.15%
Sales2.23B P/S10.13 EPS this Y304.40% Inst Trans2.05% Short Ratio4.48 Perf Half Y38.37%
Book/sh8.94 P/B12.06 EPS next Y986.40% ROA-12.20% Target Price102.07 Perf Year26.40%
Cash/sh6.22 P/C17.34 EPS next 5Y18.54% ROE-16.30% 52W Range62.48 - 110.25 Perf YTD23.44%
Dividend- P/FCF- EPS past 5Y55.60% ROI13.70% 52W High-0.87% Beta1.04
Dividend %- Quick Ratio3.40 Sales past 5Y33.40% Gross Margin95.60% 52W Low74.92% ATR3.74
Employees1456 Current Ratio3.40 Sales Q/Q14.20% Oper. Margin-15.10% RSI (14)64.67 Volatility3.48% 3.79%
OptionableYes Debt/Eq0.03 EPS Q/Q-805.50% Profit Margin-16.90% Rel Volume0.53 Prev Close107.79
ShortableYes LT Debt/Eq0.02 EarningsMay 05 BMO Payout- Avg Volume1.74M Price109.29
Recom2.30 SMA209.18% SMA5010.51% SMA20027.45% Volume206,463 Change1.39%
Jun-16-20Initiated The Benchmark Company Hold
May-06-20Downgrade JP Morgan Overweight → Neutral $89 → $99
Apr-29-20Downgrade Morgan Stanley Overweight → Equal-Weight $94
Apr-01-20Upgrade Morgan Stanley Equal-Weight → Overweight $83 → $90
Mar-24-20Resumed William Blair Outperform
Mar-13-20Upgrade BofA/Merrill Neutral → Buy $83
Feb-04-20Resumed BofA/Merrill Neutral $82
Jan-03-20Reiterated BMO Capital Markets Market Perform $85 → $74
Jan-03-20Downgrade Mizuho Buy → Neutral $98 → $79
Jan-02-20Downgrade Guggenheim Buy → Neutral
Oct-03-19Initiated Mizuho Buy $95
Sep-12-19Initiated BMO Capital Markets Market Perform
Sep-05-19Upgrade Oppenheimer Perform → Outperform $100
Sep-05-19Upgrade JMP Securities Mkt Perform → Mkt Outperform $107
Sep-05-19Resumed Morgan Stanley Equal-Weight $82 → $87
May-21-19Initiated Credit Suisse Neutral $75
May-03-19Downgrade Barclays Overweight → Equal Weight $90 → $82
Apr-11-19Initiated Stifel Hold $82
Apr-03-19Downgrade RBC Capital Mkts Outperform → Sector Perform $89
Jan-24-19Upgrade William Blair Mkt Perform → Outperform
Jun-29-20 07:05AM  
Incyte Announces Approval of Tabrecta (capmatinib) in Japan for the Treatment of Patients with Advanced Non-Small Cell Lung Cancer with METex14
Business Wire
Jun-26-20 10:37AM  
Gilead's (GILD) Remdesivir Gets CHMP Approval Recommendation
Zacks
Jun-23-20 10:24AM  
Gilead to Start Studies for an Inhaled Version of Remdesivir
Zacks
Jun-22-20 12:05PM  
Nasdaq's Excels in Weekly Performance: 5 Best Stocks in ETF
Zacks
12:05PM  
Nasdaq Continues to Excel : 5 Best Stocks in ETF
Zacks
09:34AM  
Gilead's stock falls as it announces clinical trial for inhaled remdesivir
MarketWatch
08:36AM  
Incyte (INCY) Looks Good: Stock Adds 8.3% in Session
Zacks
Jun-17-20 08:00AM  
Incyte Investor Conference Update
Business Wire
Jun-15-20 03:18PM  
Coronavirus update: U.S. death toll tops 115,000 amid growing worry about uptick in cases in Florida, Texas among others
MarketWatch
08:40AM  
Lilly Is Testing Its Arthritis Drug as a Coronavirus Treatment
Barrons.com
08:00AM  
Incyte Launches New Global Responsibility Section on Incyte.com
Business Wire
07:36AM  
Lilly's shares drop as it enrolls first patient in COVID-19 study for arthritis drug
MarketWatch
Jun-05-20 12:38PM  
MARKETS: YF Premium Investment Idea: Incyte Corporation (INCY)
Yahoo Finance Video
Jun-04-20 10:24PM  
Hedge Funds Souring On Incyte Corporation (INCY)
Insider Monkey -5.09%
11:31AM  
Why Is Incyte (INCY) Up 2.9% Since Last Earnings Report?
Zacks
Jun-03-20 08:00AM  
Incyte to Present at Upcoming Investor Conferences
Business Wire
Jun-02-20 10:00AM  
These 4 Biotech Stocks Are Outperforming Their Peers Here's Why
Investor's Business Daily
May-29-20 08:00AM  
Interim Data from the Open Label Phase 2 OPTIC Study of Iclusig® (ponatinib) for Chronic Phase-CML Presented at the ASCO and EHA Virtual Meetings
Business Wire
May-21-20 08:35AM  
Incyte, MorphoSys Application for Lymphoma Drug Validated
Zacks
08:00AM  
Incyte to Present at Upcoming Investor Conference
Business Wire
May-20-20 02:30PM  
MorphoSys and Incyte Announce the Validation of the European Marketing Authorization Application for Tafasitamab
ACCESSWIRE
02:00PM  
Incyte and MorphoSys Announce the Validation of the European Marketing Authorization Application for Tafasitamab
Business Wire
01:18PM  
Biotech Stock Roundup: MRNA, DVAX Up on Coronavirus Treatment Updates, & More
Zacks
May-14-20 12:18PM  
Data from Incytes Oncology Portfolio Accepted for Presentation at the ASCO and EHA Virtual Meetings
Business Wire
11:51AM  
Coronavirus Vaccine Progress Accelerates
Yahoo Finance
May-12-20 07:52AM  
This unlikely stock is the biggest winner since the February stock market top
MarketWatch
May-11-20 11:14AM  
Optimism Runs High for MacroGenics
GuruFocus.com
May-09-20 01:30PM  
MorphoSys AG (MOR) Q1 2020 Earnings Call Transcript
Motley Fool
May-07-20 10:24AM  
Incyte Corporation (NASDAQ:INCY) First-Quarter Results: Here's What Analysts Are Forecasting For This Year
Simply Wall St.
May-06-20 10:44PM  
Edited Transcript of INCY earnings conference call or presentation 5-May-20 12:00pm GMT
Thomson Reuters StreetEvents
02:41PM  
Incyte Announces FDA Approval of Tabrecta (capmatinib) for the Treatment of Patients with Metastatic Non-Small Cell Lung Cancer with METex14
Business Wire
09:46AM  
Company News for May 6, 2020
Zacks
07:21AM  
Incyte Reports Strong Jakafi Sales, But Recent Rally Sparks Downgrades
SmarterAnalyst
May-05-20 10:30PM  
Incyte Corp (INCY) Q1 2020 Earnings Call Transcript
Motley Fool
05:25PM  
Incyte Stock Dips Back Into Buy Zone On Surprise Loss, Delayed Study
Investor's Business Daily
02:36PM  
Why Incyte's Q1 Loss Isn't As Bad As It Looks
Motley Fool
11:24AM  
Incyte (INCY) Misses Q1 Earnings Estimates, Beats on Revenues
Zacks
11:02AM  
Incyte Reports a Q1 Loss Due to MorphoSys Deal
Motley Fool
09:15AM  
Incyte (INCY) Reports Q1 Loss, Tops Revenue Estimates
Zacks
07:00AM  
Incyte Reports 2020 First Quarter Financial Results and Provides Updates on Key Clinical Programs
Business Wire
May-04-20 08:43PM  
Disney, Beyond Meat earnings, ISM non-manufacturing: What to know in markets Tuesday
Yahoo Finance
03:38PM  
Were Hedge Funds Right About Incyte Corporation (INCY)?
Insider Monkey
May-01-20 08:00AM  
Ten Stocks Pay Off In May While Many Investors 'Stay Away'
Investor's Business Daily
Apr-30-20 12:52PM  
Incyte (INCY) to Report Q1 Earnings: What's in the Cards?
Zacks
Apr-29-20 08:00AM  
Incyte to Present at Upcoming Investor Conference
Business Wire
06:38AM  
Is Incyte Stock a Buy?
Motley Fool
Apr-28-20 12:33PM  
Analysts Estimate Incyte (INCY) to Report a Decline in Earnings: What to Look Out for
Zacks -5.16%
Apr-24-20 04:09PM  
Reasons for hope: the drugs, tests and tactics that may conquer coronavirus
Reuters
11:41AM  
7 Beautiful Biotech Stocks to Buy Here
InvestorPlace
08:00AM  
Incyte Appoints Christine Lennon as General Manager, Incyte Biosciences Canada
Business Wire
Apr-23-20 07:53AM  
The Daily Biotech Pulse: FDA Nod For Immunomedics, Lilly's Solid Q1 Beat, Predictive Oncology Restructures Debt
Benzinga
Apr-22-20 05:01PM  
Incyte Announces Pivotal REACH2 Study Data Published in NEJM Highlight Superior Efficacy of Ruxolitinib (Jakafi®) versus Best Available Therapy in Patients with Acute Graft-Versus-Host Disease
Business Wire
10:30AM  
Biotech Stock Roundup: ALXN, MRNA Up on Coronavirus Treatment Updates, & More
Zacks
Apr-21-20 04:21PM  
Why Vertex Stock Is The 'Most Insulated Name' Heading Into Earnings
Investor's Business Daily
Apr-20-20 10:31AM  
Wilmington-based Incyte receives FDA approval for therapy to treat a rare cancer
American City Business Journals
09:57AM  
Incyte Gets FDA Nod for Cholangiocarcinoma Drug Pemazyre
Zacks
07:58AM  
Incytes Bile Duct Cancer Drug Wins FDA Approval
SmarterAnalyst
Apr-19-20 09:03AM  
Incyte, Novartis Initiate Phase 3 Jakavi Drug Study For Coronavirus Treatment
SmarterAnalyst
Apr-17-20 08:53PM  
FDA Approves Incytes Pemazyre (pemigatinib) as First Targeted Treatment for Adults with Previously Treated, Unresectable Locally Advanced or Metastatic Cholangiocarcinoma
Business Wire
04:49PM  
Incyte, Novartis launch drug study to treat coronavirus complication
MarketWatch
03:46PM  
Incyte Announces Initiation of Phase 3 RUXCOVID Study Evaluating Ruxolitinib (Jakafi®) as a Treatment for Patients with COVID-19 Associated Cytokine Storm
Business Wire
11:21AM  
Reasons for hope: the drugs, tests and tactics that may conquer coronavirus
Reuters
11:05AM  
Incyte Scores New High
Investor's Business Daily Video
08:26AM  
What Is Incyte's (NASDAQ:INCY) P/E Ratio After Its Share Price Rocketed?
Simply Wall St.
Apr-16-20 04:30PM  
Intrepid Retires Series A Senior Notes; Updates 2020 Guidance and Announces Earnings Release and Conference Call Dates
GlobeNewswire +5.18%
09:23AM  
Is Incyte Corporation (NASDAQ:INCY) Trading At A 33% Discount?
Simply Wall St.
08:00AM  
Incyte to Report First Quarter Financial Results
Business Wire
Apr-14-20 11:45AM  
10 Stocks Leading the Rally in the S&P 500 ETF
Zacks
Apr-13-20 03:21PM  
Reasons for hope: the drugs, tests and tactics that may conquer coronavirus
Reuters
03:15PM  
Reasons for hope: the drugs, tests and tactics that may conquer coronavirus
Reuters
Apr-10-20 02:12PM  
Companies on the Front Lines of the Coronavirus Fight
Yahoo Finance
Apr-08-20 10:05AM  
Biotech Stock Roundup: AMGN & INCY Focus on Coronavirus Treatments, & More
Zacks
Apr-07-20 04:51PM  
Biotech Stocks, ETFs to Gain on COVID-19 Vaccine & Drug Progress
Zacks
Apr-06-20 02:46AM  
Incyte to Trial Cancer Drug for Patients with COVID-19 Associated Cytokine Storm
SmarterAnalyst +8.30%
Apr-05-20 08:00AM  
Incyte Announces First Presentation of Phase 3 Data from the TRuE-AD Program of Ruxolitinib Cream at the Revolutionizing Atopic Dermatitis Virtual Symposium
Business Wire
Apr-03-20 08:28PM  
A Simple Blood Test May Be the Answer to Getting America Back to Work
Barrons.com
10:55AM  
Wilmington-based Incyte looking to repurpose flagship drug as COVID-19 treatment
American City Business Journals
10:51AM  
Pharma Coronavirus Efforts Continue, Amgen & Incyte Join In
Zacks
10:16AM  
Novartis Enlists Bone Marrow Cancer Drug in Fight Against Covid-19
TheStreet.com
10:13AM  
A Cancer Drug From Incyte and Novartis Is Latest Potential Weapon Against Covid-19
Barrons.com
09:48AM  
Incyte to Evaluate Lead Drug Jakafi for COVID-19 Infection
Zacks
07:36AM  
The Daily Biotech Pulse: Fate Therapeutics Inks Cell Therapy Deal With J&J, Zentalis IPO
Benzinga
03:32AM  
Novartis, Incyte join repurposing wave to give Jakavi a trial run in COVID-19
Reuters
02:39AM  
RPT-Novartis, Incyte join repurposing wave to give Jakavi a trial run in COVID-19
Reuters
02:36AM  
Novartis, Incyte join repurposing wave to give Jakavi a trial run in COVID-19
Reuters
Apr-02-20 05:05PM  
Incyte Announces Plans to Initiate a Phase 3 Clinical Trial of Ruxolitinib (Jakafi®) as a Treatment for Patients with COVID-19 Associated Cytokine Storm
Business Wire
Apr-01-20 01:54PM  
Cancer startup raises $125M for Keytruda combo drug trial
American City Business Journals
Mar-26-20 02:53PM  
The Top 10 Biotechnology Companies
Investopedia
08:00AM  
Incyte Names New Member to Its Board of Directors
Business Wire
Mar-24-20 07:30AM  
Data from Phase 3 TRuE-AD Trials of Ruxolitinib Cream in Atopic Dermatitis to be Presented at the 2020 Revolutionizing Atopic Dermatitis Virtual Conference
Business Wire +6.73%
Mar-17-20 08:08AM  
Don't Sell Incyte Corporation (NASDAQ:INCY) Before You Read This
Simply Wall St.
Mar-16-20 06:45AM  
Lilly Receives FDA Breakthrough Therapy Designation for Baricitinib for the Treatment of Alopecia Areata
PR Newswire
Mar-14-20 11:30AM  
Incyte (INCY) Down 5.4% Since Last Earnings Report: Can It Rebound?
Zacks
Mar-11-20 09:23PM  
Hedge Funds Started Buying Incyte Corporation (INCY) Too Early
Insider Monkey
Mar-10-20 03:12PM  
Incyte Joins Elite List Of Stocks With 95-Plus Composite Rating
Investor's Business Daily
Mar-05-20 01:11PM  
Incyte approval triggers $750M payment for drug collaboration
American City Business Journals
Mar-04-20 09:55AM  
Biotech Stock Roundup: GILD to Buy Forty Seven, Pipeline Updates From BIIB & More
Zacks
Mar-02-20 02:45PM  
World Markets Rebound on Monday
GuruFocus.com
Feb-28-20 03:06PM  
Financial Markets Plunge on Coronavirus Outbreak
GuruFocus.com
Feb-27-20 09:00AM  
Incyte Partners with Artist and Patient J.G. Jones to Raise Awareness for Myeloproliferative Neoplasms (MPNs)
Business Wire
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of various therapeutics in the United States. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera cancers; and Iclusig, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a drug in Phase III clinical trial for steroid-refractory chronic graft-versus-host-diseases (GVHD); and Phase II trial for the treatment of essential thrombocythemia and refractory myelofibrosis. In addition, the company engages in the development of itacitinib, which is in Phase III clinical trial to treat naive chronic GVHD; and pemigatinib that is in Phase II clinical trial for treating bladder cancer, cholangiocarcinoma, 8p11 myeloproliferative syndrome, and Tumor agnostic. Further, it is involved in developing Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. Additionally, the company develops INCMGA0012 that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer, as well as in Phase II clinical trials non-small cell lung cancer. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Merus N.V.; Calithera Biosciences, Inc; MacroGenics, Inc.; Merus N.V.; MorphoSys AG; Syros Pharmaceuticals, Inc.; Innovent Biologics, Inc.; and Zai Lab Limited. The company was founded in 1991 and is headquartered in Wilmington, Delaware.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Hoppenot HerveChairman / CEOJun 26Option Exercise64.55124,1488,013,753360,104Jun 30 04:06 PM
Hoppenot HerveChairman / CEOJun 26Sale102.91124,14812,776,071240,603Jun 30 04:06 PM
Flannelly Barry PEVP & General Manager USJun 23Option Exercise73.2159943,85336,461Jun 25 05:09 PM
Trower PaulPrincipal Accounting OfficerJun 23Option Exercise64.556,943448,17128,677Jun 25 05:15 PM
Trower PaulPrincipal Accounting OfficerJun 23Sale110.006,943763,73021,734Jun 25 05:15 PM
Flannelly Barry PEVP & General Manager USJun 23Sale110.0040044,00036,061Jun 25 05:09 PM
Dickinson Jonathan ElliottEVP, General Manager, EuropeJun 22Sale105.319,000947,79021,762Jun 23 04:17 PM
Flannelly Barry PEVP & General Manager USJun 19Option Exercise73.217,181525,72143,043Jun 23 04:23 PM
Iyengar Vijay KEVP GPS, BD, & LicensingJun 19Option Exercise72.867,866573,11732,767Jun 23 04:33 PM
Pasquale Maria EEVP & General CounselJun 19Option Exercise72.271,423102,84025,084Jun 23 04:42 PM
Pasquale Maria EEVP & General CounselJun 19Sale100.001,423142,30023,661Jun 23 04:42 PM
Iyengar Vijay KEVP GPS, BD, & LicensingJun 19Sale105.007,866825,93024,901Jun 23 04:33 PM
Flannelly Barry PEVP & General Manager USJun 19Sale105.007,181754,00535,862Jun 23 04:23 PM
Pasquale Maria EEVP & General CounselJun 12Option Exercise65.361278,30123,661Jun 16 04:24 PM
Pasquale Maria EEVP & General CounselJun 10Option Exercise66.643,615240,91525,726Jun 12 04:11 PM
Pasquale Maria EEVP & General CounselJun 10Sale94.513,615341,64923,534Jun 12 04:11 PM
Dhanak DashyantEVP & Chief Scientific OfficerJun 08Option Exercise65.4296162,86920,948Jun 10 04:34 PM
Dhanak DashyantEVP & Chief Scientific OfficerJun 08Sale91.8796188,28719,987Jun 10 04:34 PM
BAKER BROS. ADVISORS LPDirectorMay 28Buy102.55220529,313,198May 28 08:07 PM
Pasquale Maria EEVP & General CounselMay 11Option Exercise65.361288,36623,534May 13 04:38 PM
Dhanak DashyantEVP & Chief Scientific OfficerMay 06Option Exercise65.4296162,86920,948May 08 04:53 PM
Dhanak DashyantEVP & Chief Scientific OfficerMay 06Sale96.8496193,06319,987May 08 04:53 PM
BAKER BROS. ADVISORS LPDirectorApr 28Option Exercise13.3440,000533,60029,311,915Apr 29 04:45 PM
Pasquale Maria EEVP & General CounselApr 17Option Exercise72.279,488685,69832,837Apr 20 05:08 PM
Flannelly Barry PEVP & General Manager USApr 17Option Exercise73.216,583481,94141,925Apr 21 04:28 PM
Trower PaulPrincipal Accounting OfficerApr 17Option Exercise64.551,14373,78122,467Apr 21 04:35 PM
Flannelly Barry PEVP & General Manager USApr 17Sale100.006,583658,30035,342Apr 21 04:28 PM
Trower PaulPrincipal Accounting OfficerApr 17Sale100.001,143114,30021,324Apr 21 04:35 PM
Pasquale Maria EEVP & General CounselApr 17Sale100.009,488948,80022,899Apr 20 05:08 PM
Pasquale Maria EEVP & General CounselApr 16Option Exercise68.629,488651,06732,837Apr 20 05:08 PM
Pasquale Maria EEVP & General CounselApr 16Sale95.009,488901,36022,899Apr 20 05:08 PM
Pasquale Maria EEVP & General CounselApr 14Option Exercise65.3617,8271,165,17340,726Apr 15 04:57 PM
Pasquale Maria EEVP & General CounselApr 14Sale90.0017,8271,604,43022,899Apr 15 04:57 PM
Pasquale Maria EEVP & General CounselApr 13Option Exercise65.361278,30123,864Apr 15 04:57 PM
Pasquale Maria EEVP & General CounselApr 13Sale85.6896582,68122,899Apr 15 04:57 PM
Dhanak DashyantEVP & Chief Scientific OfficerApr 06Option Exercise65.423,844251,47423,831Apr 08 04:35 PM
Pasquale Maria EEVP & General CounselApr 06Sale85.001,842156,57024,254Apr 08 04:39 PM
Dhanak DashyantEVP & Chief Scientific OfficerApr 06Sale85.003,844326,74019,987Apr 08 04:35 PM
SWAIN PAULA JEVP, Human ResourcesMar 31Option Exercise64.552,329150,33750,132Apr 02 05:32 PM
SWAIN PAULA JEVP, Human ResourcesMar 31Sale71.442,329166,38448,493Apr 02 05:32 PM
Pasquale Maria EEVP & General CounselMar 11Option Exercise65.361288,36626,096Mar 13 04:18 PM
BROOKE PAUL ADirectorFeb 21Option Exercise13.3420,000266,800221,584Feb 25 04:39 PM
SWAIN PAULA JEVP, Human ResourcesFeb 19Option Exercise64.552,500161,37550,993Feb 21 04:11 PM
SWAIN PAULA JEVP, Human ResourcesFeb 19Sale80.002,500200,00048,493Feb 21 04:11 PM
Pasquale Maria EEVP & General CounselFeb 10Option Exercise65.361278,30119,087Feb 12 05:00 PM
Wenqing YaoEVP, Head of Discovery ChemFeb 05Option Exercise18.3217,542321,369112,850Feb 07 04:48 PM
Wenqing YaoEVP, Head of Discovery ChemFeb 05Sale75.9717,5421,332,66695,308Feb 07 04:48 PM
SWAIN PAULA JEVP, Human ResourcesJan 15Option Exercise64.552,500161,37544,112Jan 17 04:20 PM
SWAIN PAULA JEVP, Human ResourcesJan 15Sale81.122,500202,80041,612Jan 17 04:20 PM
Pasquale Maria EEVP & General CounselJan 10Option Exercise65.361278,30118,960Jan 14 04:54 PM
SWAIN PAULA JEVP, Human ResourcesDec 16Option Exercise64.552,500161,37544,112Dec 18 04:59 PM
SWAIN PAULA JEVP, Human ResourcesDec 16Sale91.612,500229,02541,612Dec 18 04:59 PM
Pasquale Maria EEVP & General CounselDec 12Option Exercise65.36775,03318,833Dec 16 04:35 PM
Flannelly Barry PEVP & General Manager USDec 02Option Exercise73.216,582481,86823,561Dec 03 04:20 PM
Iyengar Vijay KEVP GPS, BD, & LicensingDec 02Option Exercise72.867,366536,68724,975Dec 03 04:25 PM
Wenqing YaoEVP, Head of Discovery ChemDec 02Option Exercise18.3216,835308,417112,143Dec 03 04:32 PM
Flannelly Barry PEVP & General Manager USDec 02Sale95.006,582625,29016,979Dec 03 04:20 PM
Iyengar Vijay KEVP GPS, BD, & LicensingDec 02Sale95.007,366699,77017,609Dec 03 04:25 PM
Wenqing YaoEVP, Head of Discovery ChemDec 02Sale95.0016,8351,599,32595,308Dec 03 04:32 PM
Iyengar Vijay KEVP GPS, BD, & LicensingNov 29Option Exercise72.8650036,43018,109Dec 03 04:25 PM
Flannelly Barry PEVP & General Manager USNov 29Option Exercise73.2160043,92617,579Dec 03 04:20 PM
Wenqing YaoEVP, Head of Discovery ChemNov 29Option Exercise18.323,16557,98398,473Dec 03 04:32 PM
Flannelly Barry PEVP & General Manager USNov 29Sale95.0060057,00016,979Dec 03 04:20 PM
Iyengar Vijay KEVP GPS, BD, & LicensingNov 29Sale95.0050047,50017,609Dec 03 04:25 PM
Wenqing YaoEVP, Head of Discovery ChemNov 29Sale95.003,165300,67595,308Dec 03 04:32 PM
Wenqing YaoEVP, Head of Discovery ChemNov 25Option Exercise18.3215,000274,800110,308Nov 26 04:11 PM
Flannelly Barry PEVP & General Manager USNov 25Option Exercise48.442,142103,75818,699Nov 26 04:31 PM
Trower PaulPrincipal Accounting OfficerNov 25Option Exercise18.3215,000274,80032,306Nov 26 04:06 PM
Flannelly Barry PEVP & General Manager USNov 25Sale90.002,142192,78016,979Nov 26 04:31 PM
Wenqing YaoEVP, Head of Discovery ChemNov 25Sale90.0015,0001,350,00095,308Nov 26 04:11 PM
Trower PaulPrincipal Accounting OfficerNov 25Sale90.0015,0001,350,00017,306Nov 26 04:06 PM
SWAIN PAULA JEVP, Human ResourcesNov 15Option Exercise64.552,500161,37544,112Nov 19 05:45 PM
SWAIN PAULA JEVP, Human ResourcesNov 15Sale86.462,500216,15041,612Nov 19 05:45 PM
Pasquale Maria EEVP & General CounselNov 13Option Exercise65.36764,96718,756Nov 14 05:32 PM
DIXON WENDY LDirectorNov 08Option Exercise12.4641,218513,57635,224Nov 08 05:25 PM
DIXON WENDY LDirectorNov 08Sale83.8741,2183,456,95412,340Nov 08 05:25 PM
DIXON WENDY LDirectorNov 07Option Exercise12.461,54019,18813,880Nov 08 05:25 PM
DIXON WENDY LDirectorNov 07Sale83.601,540128,74412,340Nov 08 05:25 PM
DIXON WENDY LDirectorNov 06Option Exercise12.4610,576131,77722,916Nov 08 05:25 PM
DIXON WENDY LDirectorNov 06Sale84.1610,576890,07612,340Nov 08 05:25 PM
Wenqing YaoEVP, Head of Discovery ChemNov 01Option Exercise18.327,960145,827103,268Nov 05 05:23 PM
Trower PaulPrincipal Accounting OfficerNov 01Option Exercise18.328,500155,72025,806Nov 05 04:33 PM
Wenqing YaoEVP, Head of Discovery ChemNov 01Sale85.007,960676,60095,308Nov 05 05:23 PM
Trower PaulPrincipal Accounting OfficerNov 01Sale85.008,500722,50017,306Nov 05 04:33 PM
Trower PaulPrincipal Accounting OfficerOct 29Option Exercise18.3216,500302,28025,705Oct 31 04:07 PM
Wenqing YaoEVP, Head of Discovery ChemOct 29Option Exercise18.322,04037,37347,348Oct 31 04:10 PM
Wenqing YaoEVP, Head of Discovery ChemOct 29Sale85.002,040173,40045,308Oct 31 04:10 PM
Trower PaulPrincipal Accounting OfficerOct 29Sale80.4516,5001,327,50017,306Oct 31 04:07 PM
Iyengar Vijay KEVP GPS, BD, & LicensingOct 29Sale85.0093079,05017,609Oct 31 04:00 PM
SWAIN PAULA JEVP, Human ResourcesOct 22Option Exercise64.552,500161,37544,112Oct 24 06:52 PM
SWAIN PAULA JEVP, Human ResourcesOct 22Sale80.002,500200,00041,612Oct 24 06:52 PM
Pasquale Maria EEVP & General CounselOct 10Option Exercise65.36775,03318,680Oct 11 04:40 PM
SWAIN PAULA JEVP, Human ResourcesSep 18Option Exercise64.552,500161,37544,112Sep 19 04:34 PM
SWAIN PAULA JEVP, Human ResourcesSep 18Sale80.002,500200,00041,612Sep 19 04:34 PM
Flannelly Barry PEVP & General Manager USSep 17Sale77.712,491193,57616,757Sep 19 04:30 PM
Pasquale Maria EEVP & General CounselSep 09Option Exercise65.36764,96718,603Sep 11 04:29 PM
SWAIN PAULA JEVP, Human ResourcesAug 15Option Exercise64.552,500161,37544,112Aug 19 04:21 PM
SWAIN PAULA JEVP, Human ResourcesAug 15Sale80.962,500202,40041,612Aug 19 04:21 PM
Pasquale Maria EEVP & General CounselAug 09Option Exercise65.361,22379,93518,527Aug 13 04:35 PM
FRIEDMAN PAUL ADirectorAug 06Option Exercise18.3277,9341,427,751333,465Aug 06 06:45 PM
open in yahoo | open in reuters | open in google